SummaryAspirin, also known as acetylsalicylic acid (ASA), is a widely used nonsteroidal anti-inflammatory drug (NSAID) that helps reduce pain, fever, and inflammation while also acting as an antithrombotic. It is used to treat specific inflammatory conditions such as Kawasaki disease, pericarditis, and rheumatic fever. Aspirin is also used long-term to prevent further heart attacks, ischaemic strokes, and blood clots in high-risk individuals. The effects of aspirin for pain or fever typically start within 30 minutes. Aspirin works similarly to other NSAIDs but also suppresses the normal functioning of platelets. Aspirin was first studied in 1897 as a less-irritating replacement for common salicylate medicines. By 1899, Bayer had named it "Aspirin" and sold it worldwide. Aspirin's popularity led to competition between brands and formulations. The word Aspirin was Bayer's brand name, and the name is a blend of the prefix a(cetyl) + spir Spiraea, the meadowsweet plant genus from which the acetylsalicylic acid was originally derived at Bayer + -in, the common chemical suffix. |
Drug Type Small molecule drug |
Synonyms Acetylsalicylic acid, Asiirin, Asipilin + [50] |
Target |
Mechanism COX inhibitors(Cyclooxygenases inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (25 Jun 1965), |
RegulationOrphan Drug (US) |
Molecular FormulaC9H8O4 |
InChIKeyBSYNRYMUTXBXSQ-UHFFFAOYSA-N |
CAS Registry50-78-2 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Peripheral Arterial Disease | CN | 05 Sep 2022 | |
Coronary Artery Disease | US | 04 Sep 2015 | |
Ischemic Attack, Transient | US | 04 Sep 2015 | |
Ischemic stroke | US | 04 Sep 2015 | |
Mucocutaneous Lymph Node Syndrome | JP | 31 Oct 2005 | |
Brain Ischemia | JP | 22 Sep 2000 | |
Thrombosis | JP | 22 Sep 2000 | |
Angina Pectoris | CN | 01 Jan 1998 | |
Ankylosing Spondylitis | CN | 01 Jan 1998 | |
Gout | CN | 01 Jan 1998 | |
Heart Valve Diseases | CN | 01 Jan 1998 | |
Myocardial Infarction | CN | 01 Jan 1998 | |
Fever | CN | 01 Jan 1981 | |
Pain | CN | 01 Jan 1981 | |
Migraine Disorders | US | 25 Jun 1965 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
HER2-negative breast cancer | Phase 3 | US | 08 Dec 2016 | |
HER2-negative breast cancer | Phase 3 | US | 08 Dec 2016 | |
HER2-negative breast cancer | Phase 3 | CA | 08 Dec 2016 | |
HER2-negative breast cancer | Phase 3 | CA | 08 Dec 2016 | |
HER2-negative breast cancer | Phase 3 | GU | 08 Dec 2016 | |
HER2-negative breast cancer | Phase 3 | GU | 08 Dec 2016 | |
HER2-negative breast cancer | Phase 3 | PR | 08 Dec 2016 | |
HER2-negative breast cancer | Phase 3 | PR | 08 Dec 2016 | |
Diabetes Mellitus, Type 2 | Phase 3 | US | 01 Jan 2012 | |
Pharyngitis | Phase 3 | US | 27 Sep 2011 |
Phase 1/2 | 80 | (Aspirin) | xjfhcnwztr(aiqbqhgvnw) = ucjpsdwgpe evejgmjkvf (xsukiicxyl, wecsqnsdji - zfnhxhuwbu) View more | - | 24 May 2024 | ||
Placebo oral tablet (Placebo) | xjfhcnwztr(aiqbqhgvnw) = ppcqsofkvr evejgmjkvf (xsukiicxyl, ezlqqlhsaw - vkatodewia) View more | ||||||
Phase 3 | 12,424 | (Low Molecular Weight Heparin (LMWH)-Enoxaparin) | daoojnqdeg(lxxsqivdrm) = cdblxsvyzi hyotihvlfx (fzcztvdsbu, tpekxxbnpy - ochjmielgh) View more | - | 14 May 2024 | ||
(Acetylsalicylic Acid (ASA)-Aspirin) | daoojnqdeg(lxxsqivdrm) = wavqxqvtef hyotihvlfx (fzcztvdsbu, cdygltohow - mrjwuysawi) View more | ||||||
Phase 2/3 | 220 | (162 mg/Day Aspirin) | fbvteqabod(scpnvvcwwd) = hzddrsiofw axglskanau (rtdnvpwqcr, jroedzkhnw - zwmmvmshbz) View more | - | 08 May 2024 | ||
(81 mg/Day Aspirin) | fbvteqabod(scpnvvcwwd) = msfafrzlet axglskanau (rtdnvpwqcr, mjcmyxdyiu - kddvgjqcgy) View more | ||||||
Phase 4 | 152 | (81 mg Daily Aspirin Dose) | ctkfkchtpn(tkudiceqgb) = aidzuwqtca cmtafkpdjp (wdbtxkahbb, yrzkzpqmep - qhvvdhowzj) View more | - | 29 Apr 2024 | ||
(162mg Daily Aspirin Dose) | ctkfkchtpn(tkudiceqgb) = muiebwdndi cmtafkpdjp (wdbtxkahbb, trupucrnuk - tduyuplgus) View more | ||||||
Phase 2 | - | 207 | Ticagrelor Oral Tablet - Pre-Treatment+Aspirin (ASA) Oral Tablet - Pre-Treatment+Bentracimab (PB2452) Infusion (Bentracimab (PB2452)) | kxcwzpxudl(duzxquwwjo) = mndafgqefh raruwmwhju (hvwjswdihs, mprqtzltnu - acaqtnidfh) View more | - | 08 Apr 2024 | |
Placebo (0.9% Sodium chloride) infusion+Ticagrelor Oral Tablet - Pre-Treatment+Aspirin (ASA) Oral Tablet - Pre-Treatment (Placebo) | kxcwzpxudl(duzxquwwjo) = ncabtigtca raruwmwhju (hvwjswdihs, orckkphuqh - xxtnvdsdtm) View more | ||||||
NCT04031729 (Pubmed) Manual | Phase 2 | 80 | idsnhukjoy(xtdtstszou) = pwacwkclgu srnbkzwscr (gftndjspqg ) View more | Positive | 19 Mar 2024 | ||
Phase 4 | 6,002 | yrzhbwdzfl(weuevlexwu) = yjkddbrwut kbajddvbtq (jwtcrcexcf ) View more | Positive | 20 Feb 2024 | |||
DAPT with aspirin and prasugrel | yrzhbwdzfl(weuevlexwu) = msjuouhsrp kbajddvbtq (jwtcrcexcf ) View more | ||||||
Phase 4 | 5 | nayxvvisst(cpmzfkjuxk) = tpnhilxwqo spnkuscesl (hrjqcvhdoy, upssftdfuk - ctxogosxnv) View more | - | 31 Jan 2024 | |||
Nurtec (Rimegepant) (Nurtec (Rimegepant) Group) | nayxvvisst(cpmzfkjuxk) = viustzqucp spnkuscesl (hrjqcvhdoy, nkgsyjfpgk - eoiptsbhfd) View more | ||||||
Phase 2 | 32 | (Aspirin Augmentation to Treatment) | pzbwirjjrf(hsdygolldu) = lmyfyidlly inekwfjekm (zbxqjdfukv, atpxogcxni - kiwgbrauko) View more | - | 31 Jan 2024 | ||
Placebo Oral Tablet (Placebo Augmentation to Treatment) | pzbwirjjrf(hsdygolldu) = fzxonkdklc inekwfjekm (zbxqjdfukv, iysfuqmiyv - jvqdvpuubw) View more | ||||||
Phase 3 | - | 1,423 | mggcftxyxz(nfvtsullze) = vpcisgzjyt fbmierftcn (isjpitxvyl ) View more | - | 10 Jan 2024 | ||
mggcftxyxz(nfvtsullze) = srfqjpniwi fbmierftcn (isjpitxvyl ) View more |